Eloxx Pharmaceuticals Inc (ELOX)

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq PR Newswire ARLINGTON, Mass., June 8...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential...

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of...

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405

Form 8-K - Current report

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Form 8-K - Current report

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare...

Form 4 - Statement of changes in beneficial ownership of securities